

Insulin Resistance and Hyperinsulinemia Are Related to Plasma Aldosterone Levels in Hypertensive Patients

GIANLUCA COLUSSI, MD
CRISTIANA CATENA, MD, PHD
ROBERTA LAPENNA, MD

ELISA NADALINI, MD
ALESSANDRA CHIUCH, MD
LEONARDO A. SECHI, MD

OBJECTIVE — An association between aldosterone and insulin resistance has been demonstrated in obesity and primary aldosteronism and in blacks with the metabolic syndrome. The aim of this study was to evaluate the relationship of plasma aldosterone with insulin sensitivity in white subjects.

RESEARCH DESIGN AND METHODS — In 356 patients with essential hypertension and 102 normotensive control subjects of comparable age and BMI, we measured, after discontinuation of treatment, plasma active renin, aldosterone, cortisol, glucose, insulin, and C-peptide levels and calculated markers of insulin sensitivity. Direct assessment of insulin sensitivity was obtained in a subset of 64 hypertensive patients by a hyperinsulinemic clamp.

RESULTS — Hypertensive patients had significantly greater fasting plasma insulin and C-peptide concentrations and homeostasis model assessment (HOMA) indexes than normotensive control subjects. A positive association with increasing plasma aldosterone concentrations was demonstrated for plasma glucose, insulin, C-peptides, and HOMA. Assessment of insulin sensitivity by clamp showed a significant decrease of the metabolic clearance rate of glucose with increasing aldosterone levels. Significant correlations were found between plasma aldosterone, plasma insulin, and C-peptide levels, HOMA, and glucose metabolic clearance rate. Blood pressure and plasma potassium, plasma cortisol, and renin levels, but not BMI, were also directly correlated with plasma aldosterone. Multiple regression analysis showed that HOMA, together with plasma potassium, cortisol, and renin levels, was independently correlated with plasma aldosterone.

CONCLUSIONS — This study demonstrates a direct relationship between aldosterone, insulin resistance, and hyperinsulinemia in white subjects. In patients with hypertension, this relationship might contribute to maintenance of high blood pressure and increased cardiovascular risk.

Diabetes Care 30:2349–2354, 2007

Seminal studies that were published >20 years ago demonstrated an association between hyperinsulinemia, insulin resistance, and arterial hypertension (1,2). This association was confirmed even after adjustment for body weight and was present in whites but not

in blacks (3). Population-based studies have subsequently suggested that insulin resistance and hyperinsulinemia might contribute to progression of cardiovascular disease (4).

Elevated plasma aldosterone levels have been implicated in the development

and maintenance of high blood pressure in different ethnic groups (5), with a relationship that is stronger in blacks (5) and in obese subjects (6). In the Framingham Offspring Study, normotensive subjects with elevated plasma aldosterone levels, albeit within the normal range, were at high risk of blood pressure elevation and subsequent development of hypertension (7). Moreover, recent evidence indicates that chronic exposure to elevated aldosterone levels might result in substantial damage of the heart and blood vessels. This damage appears to be independent of the blood pressure level and might contribute to an increased risk of cardiovascular events (8).

A relationship between aldosterone and insulin resistance has been consistently demonstrated in obesity (9) and primary aldosteronism (10). Two recent studies that have been conducted in families of African descent in the Seychelles (11) and in African Americans (12) have demonstrated that plasma aldosterone, but not plasma renin, is associated with the metabolic syndrome and with markers of insulin resistance. The present study has evaluated the relationship of plasma aldosterone with glucose metabolism and insulin sensitivity in white patients, the majority of whom had essential hypertension.

RESEARCH DESIGN AND METHODS

A total of 356 patients with mild to moderate essential hypertension who were referred to the hypertension clinic of our department were included in a cross-sectional study. High blood pressure (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg) was measured at least twice on two different occasions and subsequently confirmed on at least two more visits during the next 4 weeks. Blood pressure was measured by a mercury sphygmomanometer after each subject had been supine for 15 min. The average of three readings obtained in 5 min was recorded. The study patients seen at our clinic are white, include individuals with all grades of hypertension living in north-east Italy, and are representative of hyper-

From the Hypertension and Diabetes Unit, Division of Internal Medicine, Department of Experimental and Clinical Pathology and Medicine, University of Udine, Udine, Italy.

Address correspondence and reprint requests to Leonardo A. Sechi, MD, Clinica Medica, University of Udine, Department of Experimental and Clinical Pathology and Medicine, Piazzale S. Maria della Misericordia, 1 Udine 33100, Italy. E-mail: sechi@uniud.it.

Received for publication 16 March 2007 and accepted in revised form 8 June 2007.

Published ahead of print at <http://care.diabetesjournals.org> on 15 June 2007. DOI: 10.2337/dc07-0525. Additional information for this article can be found in an online appendix at <http://dx.doi.org/10.2337/dc07-0525>.

Abbreviations: HOMA, homeostasis model assessment; QUICKI, quantitative insulin sensitivity check index.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2007 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

tensive patients in this geographic area. Patients with secondary hypertension, severe hypertension (as defined by diastolic blood pressure ≥ 120 mmHg), renal failure with creatinine clearance < 30 ml/min per 1.73 m² of body surface area, urinary protein excretion ≥ 1.0 g/day, pregnancy, chronic debilitating illness, and recent (within 6 months) myocardial infarction, unstable angina, or stroke were excluded. Secondary causes of hypertension were identified on the basis of extensive laboratory testing (13). Primary aldosteronism was screened by the demonstration of an increased plasma aldosterone-to-renin ratio in the presence of a plasma aldosterone concentration > 150 pg/ml and confirmed by the lack of aldosterone suppression following an intravenous saline load (10,14). All measurements were performed under a normal sodium diet, and 24-h urinary sodium excretion was assessed in all patients. Patients treated with antihypertensive drugs were withdrawn from treatment a minimum of 2 weeks before diagnostic assessment. No patient was taking aldosterone antagonists.

Patients with essential hypertension were compared with 102 normotensive subjects who were selected from the general population of the same geographic area as the hypertensive patients after specification of inclusion criteria to avoid age and BMI as potential confounding variables. Normotensive control subjects were not taking any regular medications and did not have any concomitant disease. Informed consent was obtained from the study participants, and the study protocol received approval by the local review committee.

Glucose metabolism evaluation and laboratory measurements

Assessment of glucose metabolism parameters and insulin sensitivity was done at the same time as diagnostic screening after appropriate antihypertensive drugs wash-out, as previously described (15). At the time of the study, patients maintained their usual unrestricted diet. A sample of venous blood was obtained after fasting for 12–14 h and after the patients were in the sitting position for 10 min for analysis of glucose, insulin, and C-peptide. The homeostasis model assessment (HOMA) index and the quantitative insulin sensitivity check index (QUICKI) were calculated as markers of sensitivity to insulin (15). The HOMA index was calculated from fasting plasma glucose (millimoles per liter) and insulin

Table 1—Clinical characteristics, laboratory variables, and glucose metabolism parameters of the study subjects

	Normotensive group	Hypertensive group	P
Clinical characteristics			
<i>n</i>	102	356	—
Age (years)	51 \pm 14	49 \pm 12	0.154
Sex (male)	71 (70)	195 (55)	0.028
SBP (mmHg)	129 \pm 11	160 \pm 19	< 0.001
DBP (mmHg)	79 \pm 7	100 \pm 11	< 0.001
BMI (kg/m ²)	28.3 \pm 3.6	27.9 \pm 4.8	0.435
Laboratory variables			
Plasma sodium (mmol/l)	141 \pm 2	141 \pm 3	1.000
Plasma potassium (mmol/l)	4.3 \pm 0.3	4.0 \pm 0.4	< 0.001
Plasma creatinine (μ mol/l)	84 \pm 25	88 \pm 17	0.062
Urinary sodium (mmol/24 h)	120 \pm 52	132 \pm 67	0.098
Urinary potassium (mmol/24 h)	46 \pm 23	56 \pm 23	< 0.001
Plasma active renin (pg/ml)	9.2 \pm 10.7	10.8 \pm 17.0	0.575
Plasma aldosterone (pg/ml)	131 \pm 77	167 \pm 123	0.005
Plasma cortisol (nmol/l)	429 \pm 107	420 \pm 236	0.709
Triglycerides (mmol/l)	1.25 \pm 0.56	1.40 \pm 0.92	0.118
Total cholesterol (mmol/l)	5.30 \pm 1.04	5.58 \pm 1.13	0.025
HDL cholesterol (mmol/l)	1.43 \pm 0.41	1.42 \pm 0.42	0.831
LDL cholesterol (mmol/l)	3.31 \pm 0.98	3.55 \pm 1.05	0.039
Glucose metabolism parameters			
Plasma glucose (mmol/l)	4.8 \pm 0.9	5.1 \pm 1.2	0.020
Plasma insulin (pmol/l)	55.9 \pm 21.7	70.0 \pm 35.1	< 0.001
Plasma C-peptide (nmol/l)	0.53 \pm 0.20	0.69 \pm 0.30	< 0.001
HOMA index	1.65 \pm 0.64	2.29 \pm 1.55	< 0.001
QUICKI	0.354 \pm 0.013	0.348 \pm 0.030	0.050

Data are means \pm SD or *n* (%) unless otherwise indicated. Comparisons were done by Student's *t* test for unpaired data. DBP, diastolic blood pressure; SBP, systolic blood pressure.

(microunits per millimeter) using the following formula: [(glucose \times insulin)/22.5]. Logarithmic values of fasting plasma glucose (milligrams/deciliter) and insulin (microunits per millimeter) concentrations were obtained to calculate the QUICKI using the following formula: $1/[\log \text{glucose} + \log \text{insulin}]$.

Insulin sensitivity was further and directly assessed in a subgroup of 64 patients with hypertension by a hyperinsulinemic-euglycemic clamp that was performed as previously described (15). Briefly, a priming dose of 100 mU/kg body wt of rapidly acting insulin was administered intravenously over a period of 10 min, and then a sustained infusion of insulin at a rate of 2 mU \cdot kg body wt⁻¹ \cdot min⁻¹ was started to maintain serum insulin concentrations at ~ 700 pmol/l. Concomitantly, an intravenous infusion of a 20% glucose solution was started to stabilize blood glucose values at 5.0 mmol/l. For this purpose, plasma glucose was determined every 10 min during the clamp. Sensitivity to insulin was ex-

pressed as the glucose metabolic clearance rate (milliliters per kg body weight per minute) during 60 min of the clamp.

Sodium, potassium, and creatinine were measured in plasma obtained after fasting for 12–14 h by automated analyzers. Plasma glucose was assayed using the glucose oxidase method. Plasma insulin and C-peptides were measured by radioimmunoassay in plasma samples obtained with patients in the sitting position. Both renin and aldosterone values were referred to the urinary sodium excretion of a 24-h collection completed on the day of sampling (17).

Statistical analysis

All values are expressed as means \pm SD. Variables with skewed distribution were analyzed after logarithmic transformation. Student's *t* test was used for comparisons between normotensive and hypertensive subjects. One-way ANOVA was used for comparisons of values when

Table 2—Clinical characteristics, laboratory variables, and glucose metabolism parameters of hypertensive patients according to plasma aldosterone tertiles

	Tertile I	Tertile II	Tertile III	P
Clinical characteristics				
n	119	118	119	—
Age (years)	50 ± 12	49 ± 12	49 ± 11	0.655
Sex (male)	62 (52)	73 (62)	60 (50)	0.161
SBP (mmHg)	157 ± 18	160 ± 18	162 ± 20	0.088
DBP (mmHg)	98 ± 10	100 ± 10	101 ± 11	0.026
BMI (kg/m ²)	27.3 ± 4.6	28.2 ± 4.7	28.3 ± 5.0	0.193
Laboratory variables				
Plasma potassium (mmol/l)	3.8 ± 0.4	4.0 ± 0.4	4.1 ± 0.4	<0.001
Urinary sodium (mmol/24 h)	133 ± 70	131 ± 68	132 ± 64	0.963
Urinary potassium (mmol/24 h)	52 ± 23	59 ± 27	58 ± 23	0.113
Plasma creatinine (μmol/l)	86 ± 15	91 ± 19	89 ± 17	0.048
Creatinine clearance (ml/min per 1.73 m ²)	94 ± 27	90 ± 24	91 ± 22	0.503
Plasma active renin (pg/ml)	9.7 ± 17.0	11.7 ± 18.9	11.1 ± 15.1	0.721
Plasma aldosterone (pg/ml)	68 ± 22	139 ± 24	293 ± 132	<0.001
Plasma cortisol (nmol/l)	356 ± 264	408 ± 213	494 ± 209	<0.001
Glucose metabolism parameters				
Plasma glucose (mmol/l)	4.8 ± 0.9	5.2 ± 1.2	5.3 ± 1.3	0.002
Plasma insulin (pmol/l)	60.3 ± 31.2	73.1 ± 35.6	76.8 ± 36.1	0.001
Plasma C-peptide (nmol/l)	0.66 ± 0.29	0.67 ± 0.32	0.75 ± 0.28	0.043
HOMA index	1.84 ± 1.28	2.40 ± 1.45	2.63 ± 1.77	<0.001
QUICKI	0.359 ± 0.029	0.345 ± 0.030	0.341 ± 0.030	<0.001

Data are means ± SD or n (%) unless otherwise indicated. Comparisons were done by one-way ANOVA. DBP, diastolic blood pressure; SBP, systolic blood pressure.

the patients were subdivided in aldosterone tertiles. Pearson's χ^2 test was used to compare frequency distributions. The relationship between continuously distributed variables was examined by linear regression analysis, and the correlation was expressed by Pearson's correlation coefficient. Stepwise multiple regression analysis was used to ascertain which variables were independently associated. Two-tailed probability values <0.05 were considered to indicate statistical significance.

RESULTS— The clinical, laboratory, and metabolic measurements of the study subjects are shown in Table 1. Plasma aldosterone levels and urinary potassium excretion were greater and plasma potassium lower in the hypertensive patients than in the normotensive control subjects, with no difference in plasma active renin or cortisol levels. In the hypertensive patients, fasting plasma glucose, insulin, and C-peptide concentrations and HOMA index were significantly different from those in normotensive control subjects, indicating the presence of insulin resistance. The percentage of hypertensive patients with plasma aldosterone above the normal range was 14.6%, and the percentage of patients with sup-

pressed plasma renin (<2.5 ng/ml) was 19.1%. Table 2 summarizes the intra-group comparison of patients with hypertension and demonstrates that increasing plasma aldosterone levels were associated with higher diastolic blood pressure and higher potassium, creatinine, and cortisol levels. Significant association with increasing plasma aldosterone was demonstrated for fasting plasma glucose, insulin, and C-peptide levels, HOMA index, and QUICKI.

In patients with hypertension, univariate analysis showed that plasma aldosterone concentrations were directly correlated with fasting plasma insulin ($r = 0.214$; $P < 0.001$), C-peptide ($r = 0.138$; $P = 0.009$), and HOMA ($r = 0.228$; $P < 0.001$) and inversely correlated with QUICKI ($r = -0.223$; $P < 0.001$) (supplementary Figure [viewable in an online appendix, available at <http://dx.doi.org/10.2337/dc07-0525>]). Plasma aldosterone was also positively correlated with systolic ($r = 0.108$; $P = 0.041$) and diastolic ($r = 0.152$; $P = 0.004$) blood pressure and plasma potassium ($r = 0.279$; $P < 0.001$), cortisol ($r = 0.255$; $P < 0.001$), and active renin ($r = 0.138$; $P = 0.023$) levels. No correlations were observed among plasma renin, blood pressure, and parameters of glucose me-

tabolism when compared with each other. BMI was significantly and directly correlated with systolic ($r = 0.110$; $P = 0.038$) and diastolic ($r = 0.152$; $P = 0.024$) blood pressure and with HOMA ($r = 0.334$; $P < 0.001$) but not with aldosterone and renin levels. Additional correlations were found between plasma potassium and HOMA ($r = 0.285$; $P < 0.001$) and QUICKI ($r = -0.239$; $P < 0.001$). Multiple regression analysis was performed with a forward stepwise approach in which variables that were significantly related to aldosterone in univariate analysis were included following the strength of the relationship. Analysis showed that plasma potassium ($P < 0.001$), plasma cortisol ($P < 0.001$), HOMA ($P = 0.009$), and plasma active renin ($P = 0.013$) were independently correlated with plasma aldosterone levels (Table 3). The relationship of aldosterone with insulin and HOMA was independent ($P < 0.001$) of blood pressure levels, and the relationship between aldosterone and blood pressure was independent ($P = 0.013$) of cortisol levels.

To further explore the relationship between plasma aldosterone and sensitivity to insulin, we measured the metabolic clearance rate of glucose in a subgroup of 64 patients with hypertension who un-

Table 3—Stepwise linear regression analysis of variables associated with plasma aldosterone levels in hypertensive patients (n = 356)

Plasma potassium		Plasma cortisol		HOMA index		Plasma active renin	
SC	P	SC	P	SC	P	SC	P
0.331	<0.001	—	—	—	—	—	—
0.287	<0.001	0.222	<0.001	—	—	—	—
0.257	<0.001	0.211	<0.001	0.153	0.010	—	—
0.259	<0.001	0.200	<0.001	0.155	0.009	0.144	0.013

Calculations were done with log-transformed values. SC, standard coefficient.

derwent a hyperinsulinemic-euglycemic clamp. In these patients, we observed a significant decrease of glucose metabolic clearance rate with increasing aldosterone levels (Fig. 1), with a highly significant inverse correlation between the rate of glucose disposal and plasma aldosterone ($r = -0.586$; $P < 0.001$).

Analysis of correlations that included both healthy control subjects and hypertensive patients demonstrated a positive and highly significant relationship between plasma aldosterone and fasting plasma insulin ($r = 0.208$; $P < 0.001$), fasting plasma C-peptide ($r = 0.161$; $P < 0.001$), and HOMA ($r = 0.243$; $P < 0.001$). Multivariate analysis showed that the relationship of plasma aldosterone with HOMA ($P = 0.008$) was independent of blood pressure, active renin, and cortisol.

CONCLUSIONS— The results of the present study demonstrate that plasma aldosterone levels are associated with plasma markers of insulin resistance and hyperinsulinemia in a white population of

patients, the majority of whom had high blood pressure. Multivariate analysis demonstrates that this association is independent of plasma potassium and cortisol levels. In patients with hypertension, the relationship between aldosterone and decreased sensitivity to insulin was confirmed by direct assessment of insulin-mediated glucose disposal rates under a hyperinsulinemic-euglycemic clamp.

The issue of a possible relationship between plasma aldosterone and insulin resistance is important because aldosterone has been shown to contribute, independent of blood pressure, to the development of cardiovascular damage (8) and because insulin resistance and hyperinsulinemia are predictors of cardiovascular events in hypertensive patients (18), as in the general population (4). Initial demonstrations of an association between plasma aldosterone levels and insulin resistance were obtained in obese subjects (9) and patients with primary aldosteronism (10). In these patients, weight loss (9) and removal of the effects of excess aldosterone with either adrenal-

ectomy or treatment with aldosterone antagonists (10) restored normal sensitivity to insulin. More recently, two large studies have reported that plasma aldosterone, but not plasma renin levels, are associated with the metabolic syndrome (11,12) and markers of insulin resistance (12) in normotensive and hypertensive blacks. In contrast, in a subanalysis of the Trial of Preventing Hypertension Study (19), no evidence for elevated aldosterone was found in individuals with high normal blood pressure and the metabolic syndrome when compared with that in control subjects without the syndrome. In that study, however, 82% of patients were white, raising the issue of a race-specific effect. Our findings extend the evidence of a significant association between aldosterone, hyperinsulinemia, and insulin resistance to white subjects. Because the majority of the individuals included in our study had hypertension, it could be speculated that aldosterone and insulin resistance might together contribute to rising blood pressure and, eventually, increased cardiovascular risk.

The methodology required to measure insulin sensitivity is complex, and this makes the translation of research findings on insulin resistance into clinical practice rather difficult. Previous studies (11,12,19) have defined insulin resistance by use of fasting plasma glucose and insulin values rather than by the gold standard, the euglycemic-hyperinsulinemic clamp. Our study is the first to provide direct assessment of insulin-mediated glucose disposal rate and to demonstrate, with this technique, a strong association between elevated plasma aldosterone and decreased sensitivity to insulin. Although an association does not necessarily imply causality, the strength of the inverse relationship between aldosterone and the metabolic clearance rate of glucose clearly suggests the possibility that elevated aldosterone might cause or, alternatively, be the result of insulin resistance.

The interaction between mineralocorticoid hormones and insulin that is suggested by the present findings is supported by substantial experimental evidence (rev. in 20,21). It was initially thought that the cause leading to glucose intolerance in conditions characterized by increased plasma aldosterone, such as primary aldosteronism, is potassium depletion, which could modulate both pancreatic insulin secretion and insulin receptor function (22,23). In this study,




Figure 1— Bar graph showing the glucose metabolic clearance rate, as assessed during a euglycemic-hyperinsulinemic clamp, across plasma aldosterone tertiles in patients with essential hypertension (n = 356). Comparisons were done by one-way ANOVA ($P < 0.001$) followed by group-to-group comparisons. MCR, metabolic clearance rate.

plasma aldosterone was correlated with hyperinsulinemia and markers of insulin resistance independent of plasma potassium, ruling out a possible role for this electrolyte in mediating the relationship. On the other hand, aldosterone might exert direct effects on insulin receptors (22), and recent experiments indicate that aldosterone might decrease insulin sensitivity in human adipocytes (24). Finally, it is possible that greater aldosterone levels might result from hyperinsulinemia (25,26) or might be related to the association between insulin resistance and body fat content. Fatty acids and adipokines released from adipose tissue play a key role in the development of insulin resistance (27) and have been shown to stimulate aldosterone production (9,28). Moreover, experimental observations indicate that fat cells can directly stimulate aldosterone secretion by adrenal glands in vitro (29).

Plasma aldosterone (5–7), hyperinsulinemia, and insulin resistance (1–3) can contribute to maintenance of increased blood pressure in the hypertensive population through several mechanism. In this study, we have observed significant reciprocal and independent correlations between aldosterone, insulin, and blood pressure, suggesting the possibility that interactions between these hormones might affect regulation of blood pressure. For instance, insulin has been shown to modulate the blood pressure response to aldosterone (30), and decrease in plasma aldosterone could contribute to the change of blood pressure with weight loss and resulting plasma insulin reduction (31). Also, in studies conducted in hyperinsulinemic rodents, a lack of aldosterone suppression by salt has been demonstrated (32). Relevant to this issue, it should be noticed that, in our study, systolic blood pressure had a weaker relationship with plasma aldosterone than diastolic blood pressure, as a likely result of its greater intrinsic variability. Plasma aldosterone was also positively correlated with plasma cortisol, but this relationship did not appear to be relevant for either blood pressure or insulin sensitivity.

Some limitations of this study need to be highlighted. First, the cross-sectional design does not permit the establishment of clear evidence of a causal relationship between aldosterone and insulin resistance, nor the establishment of which of the two is the causative factor. Second, although this study was designed to have high statistical power, some additional as-

sociations, such as those between aldosterone and BMI, that have been reported in previous studies (12,33,34) might have been missed because the average BMI of our hypertensive patients was relatively low, compared with that of hypertensive patients included in those studies. In this context, measurement of waist circumference, as a more specific indicator of visceral adipose tissue, would have been useful.

This study demonstrates a significant relationship between aldosterone and insulin resistance with use of the clamp and extends to whites the relationship previously demonstrated in studies performed in blacks. The interaction between increased aldosterone and insulin resistance could contribute to maintenance of hypertension and increase the risk of cardiovascular events in these subjects. Further studies will be necessary to establish whether increased aldosterone decreases peripheral sensitivity to insulin or, alternatively, whether insulin resistance with ensuing hyperinsulinemia stimulates aldosterone production. It would be also worth testing the possibility that pharmacological interventions with aldosterone antagonists would be particularly beneficial on the clinical outcome of patients with insulin resistance and that insulin sensitizers would favorably affect the course of clinical conditions characterized by high circulating levels of aldosterone.

Acknowledgments— This work was supported by grants from the Italian Ministry of the University to L.A.S. and C.C. and by grants from the Italian Society of Hypertension to G.L.C. and E.N.

References

1. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z: Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. *J Clin Invest* 75:809–817, 1985
2. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S: Insulin resistance in essential hypertension. *N Engl J Med* 317:350–357, 1987
3. Saad MF, Lillioja S, Nyomba BL, Castillo C, Ferraro R, De Gregorio M, Ravussin R, Knowler WC, Bennet PH, Howard BV: Racial differences in the relation between blood pressure and insulin resistance. *N Engl J Med* 324:733–739, 1991
4. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk

- factor for ischemic heart disease. *N Engl J Med* 334:952–957, 1996
5. Grim CE, Cowley AW Jr, Hamet P, Gaudet D, Kaldunski ML, Kotchen JM, Krishnaswami S, Pausova Z, Roman R, Tremblay J, Kotchen TA: Hyperaldosteronism and hypertension: ethnic differences. *Hypertension* 45:766–772, 2005
 6. Goodfriend TL, Calhoun DA: Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. *Hypertension* 43:518–524, 2004
 7. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. *N Engl J Med* 351:33–41, 2004
 8. Rossi GP, Boscaro M, Ronconi V, Funder JW: Aldosterone as a cardiovascular risk factor. *Trends Endocrinol Metab* 16:104–107, 2005
 9. Goodfriend TL, Egan BM, Kelley DE: Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. *Prostaglandins Leukot Essent Fatty Acids* 60:401–405, 1999
 10. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Novello M, Favret G, Melis A, Cavarape A, Sechi LA: Insulin sensitivity in patients with primary aldosteronism: a follow-up study. *J Clin Endocrinol Metab* 91:3457–3463, 2006
 11. Bochud M, Nussberger J, Bovet P, Mailard MR, Elston RC, Paccaud F, Shamlaye C, Burnier M: Plasma aldosterone is independently associated with the metabolic syndrome. *Hypertension* 48:239–245, 2006
 12. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ, Kotchen TA: Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. *Hypertension* 49:1–8, 2007
 13. Sechi LA, Kronenberg F, De Carli S, Falletti E, Zingaro L, Catena C, Utermann G, Bartoli E: Association of serum lipoprotein (a) levels and apolipoprotein (a) size polymorphism with target-organ damage in arterial hypertension. *JAMA* 277:1689–1695, 1997
 14. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr: Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. *J Clin Endocrinol Metab* 89:1045–1050, 2004
 15. Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S: Abnormalities of glucose metabolism in patients with early renal failure. *Diabetes* 51:1226–1232, 2002
 16. Sechi LA, Melis A, Tedde R: Insulin hypersecretion: a distinctive feature between essential and secondary hypertension. *Metabolism* 41:1261–1266, 1992
 17. Sealey JE, Gordon RD, Mantero F: Plasma renin and aldosterone measurements in low renin hypertensive states. *Trends En-*

- doocrinol Metab* 16:86–91, 2005
18. Reaven GM: Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. *J Clin Endocrinol Metab* 88:2399–2403, 2003
 19. Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandes J, Riehle JE, Nesbitt S, Michelson E, Julius S: Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. *Am J Hypertens* 18:3–12, 2005
 20. Giacchetti G, Sechi LA, Rilli S, Carey RM: The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. *Trends Endocrinol Metab* 3:120–126, 2005
 21. Corry DB, Tuck M: The effect of aldosterone on glucose metabolism. *Curr Hypertens Rep* 5:106–109, 2003
 22. Henquin JC: Triggering and amplifying pathways of regulation of insulin secretion by glucose. *Diabetes* 49:1751–1760, 2000
 23. Plavinik FL, Rodrigues CI, Zanella MT, Ribeiro AB: Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. *Hypertension* 19(Suppl. 2): 26–29, 1992
 24. Kraus D, Jager J, Meier B, Fasshauer M, Klein J: Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. *Horm Metab Res* 37:455–459, 2005
 25. Petrasek D, Jensen G, Tuck M, Stern N: In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells. *Life Sci* 50:1781–1787, 1992
 26. Haenni A, Reneland R, Lind L, Lithell H: Serum aldosterone changes during hyperinsulinemia are correlated to body mass index and insulin sensitivity in patients with essential hypertension. *J Hypertens* 19:107–112, 2001
 27. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. *Lancet* 365:1415–1428, 2005
 28. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K: Epoxy-keto derivative of linolenic acid stimulates aldosterone secretion. *Hypertension* 43:358–363, 2004
 29. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Lagenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA, Bornstein SR: Human adipocytes secrete mineralocorticoid-releasing factors. *Proc Natl Acad Sci U S A* 100:14211–14216, 2003
 30. Rocchini AP, Moorehead C, DeRemer S, Goodfriend TL, Ball DL: Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. *Hypertension* 15:861–866, 1990
 31. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, Martin M: The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. *N Engl J Med* 321:580–585, 1989
 32. Huang DY, Boini KM, Osswald H, Friedrich B, Artunc F, Ullrich S, Rajamanickam J, Palmada M, Wulff P, Kuhl D, Vallon V, Lang F: Resistance of mice lacking the serum- and glucocorticoid-inducible kinase SGK1 against salt-sensitive hypertension induced by a high-fat diet. *Am J Physiol Renal Physiol* 29:F1264–F1273, 2006
 33. Goodfriend TL, Egan BM, Kelley DE: Aldosterone in obesity. *Endocr Res* 24:789–796, 1998
 34. Rocchini AP, Katch VL, Grekin R, Moorehead C, Anderson J: Role for aldosterone in blood pressure regulation of obese adolescents. *Am J Cardiol* 57:613–618, 1986